In summary, the major apparent hurdle is that therapies targeting the SphK/S1P rheostat in cancer patients (for cancer therapy) may prove to be a double-edged sword where predisposing conditions such as obesity and diabetes are also presented. The gene discussed is MBTPS1; the disease is obesity due to melanocortin 4 receptor deficiency.